Volume 53, Issue 6, Pages (June 2008)

Slides:



Advertisements
Similar presentations
Volume 42, Issue 1, Pages 7-11 (July 2002)
Advertisements

Volume 50, Issue 3, Pages (September 2006)
Volume 63, Issue 1, Pages (January 2013)
Medical Management for BPH: The Role of Combination Therapy
Volume 59, Issue 2, Pages (February 2011)
Volume 71, Issue 2, Pages (February 2017)
The PSA Era is not Over for Prostate Cancer
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 68, Issue 3, Pages (September 2015)
Volume 191, Issue 3, Pages (March 2014)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Volume 67, Issue 1, Pages (January 2015)
Volume 64, Issue 5, Pages (November 2013)
Volume 54, Issue 6, Pages (December 2008)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Volume 67, Issue 6, Pages (June 2015)
Volume 73, Issue 1, Pages (January 2018)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 71, Issue 2, Pages (February 2017)
Volume 49, Issue 5, Pages (May 2006)
Prostate Cancer Epidemic in Sight?
Rowland Illing  European Urology Supplements 
Can Low-Intensity Extracorporeal Shockwave Therapy Improve Erectile Function? A 6- Month Follow-up Pilot Study in Patients with Organic Erectile Dysfunction 
Volume 59, Issue 2, Pages (February 2011)
Volume 55, Issue 2, Pages (February 2009)
Volume 69, Issue 2, Pages (February 2016)
Volume 63, Issue 1, Pages (January 2013)
Volume 60, Issue 4, Pages (October 2011)
Back to the Future: Introduction and Conclusions
Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)  Raymond C. Rosen, Francois Giuliano, Culley.
Volume 51, Issue 1, Pages (January 2007)
Volume 52, Issue 3, Pages (September 2007)
Volume 68, Issue 5, Pages (November 2015)
Volume 56, Issue 3, Pages (September 2009)
Rowland Illing  European Urology Supplements 
Volume 60, Issue 1, Pages (July 2011)
Volume 56, Issue 1, Pages (July 2009)
Volume 58, Issue 3, Pages (September 2010)
Volume 60, Issue 4, Pages (October 2011)
Volume 61, Issue 3, Pages (March 2012)
Volume 68, Issue 4, Pages (October 2015)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 55, Issue 2, Pages (February 2009)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Richard C. Harkaway  European Urology Supplements 
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 3, Pages (September 2006)
Volume 46, Issue 5, Pages (November 2004)
Volume 50, Issue 5, Pages (November 2006)
Volume 51, Issue 1, Pages (January 2007)
Volume 74, Issue 5, Pages (November 2018)
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Volume 54, Issue 6, Pages (December 2008)
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
C.G Roehrborn, T McNicholas  European Urology Supplements 
Volume 52, Issue 6, Pages (December 2007)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving.
End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy  Jeanette C. Reece,
Michael Marberger  European Urology Supplements 
Presentation transcript:

Volume 53, Issue 6, Pages 1236-1244 (June 2008) A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia  Christian G. Stief, Hartmut Porst, Dieter Neuser, Manfred Beneke, Ernst Ulbrich  European Urology  Volume 53, Issue 6, Pages 1236-1244 (June 2008) DOI: 10.1016/j.eururo.2008.01.075 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Flowchart showing patients’ progress throughout the study. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 The least square mean International Prostate Symptom Score (IPSS) total score for the vardenafil and placebo groups (intention-to-treat [ITT] population). A reduced score indicates an improvement in lower urinary tract symptoms (LUTS). * The p value indicates a significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 The least square mean International Prostate Symptom Score (IPSS) obstructive (a) and irritative (b) subscores for the vardenafil and placebo groups (intention-to-treat [ITT] population). A reduced score indicates an improvement in lower urinary tract symptoms (LUTS). * The p values indicate a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 The least square mean erectile function domain score of the International Index of Erectile Function (IIEF-EF) score for the vardenafil and placebo groups in (intention-to-treat [ITT] population). An increased score indicates an improvement erectile function. * The p value indicates a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 The least square mean Urolife QoL-9 total score (a), “well-being” score (b), “interference with activities” score (c), and “perceived sexual life” score (d) for the vardenafil and placebo groups (intention-to-treat [ITT] population). An increased score indicates an improvement in quality of life (QoL). * The p values indicate whether there was a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions